Vandortuzumab, the novel immunoglobulin, is an intriguing therapeutic agent targeting CD40, a key target involved in immune reaction. This mechanism for action involves blocking CD40 communication, seemingly causing to https://www.targetmol.com/compound/vandortuzumab